Does Rallies show 13F holders for BBNX?

Yes. Rallies tracks hedge fund and 13F ownership data for BBNX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is BBNX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BBNX. It does not provide personalized investment advice.

BBNX (Beta Bionics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Beta Bionics, Inc. Common Stock (BBNX) is a publicly traded Healthcare sector company. As of May 21, 2026, BBNX trades at $10.11 with a market cap of $418.88M and a P/E ratio of 0.00. BBNX moved +7.43% today. Year to date, BBNX is -65.81%; over the trailing twelve months it is -36.17%. Its 52-week range spans $8.80 to $32.71. Analyst consensus is strong buy with an average price target of $19.00. Rallies surfaces BBNX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns BBNX stock?

Hedge funds tracked by Rallies that own BBNX include Farallon Capital and Soros Fund. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Beta Bionics, Inc. Common Stock.

BBNX Key Metrics

Key financial metrics for BBNX
Metric	Value
Price	$10.11
Market Cap	$418.88M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$32.71
52-Week Low	$8.80
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Top Hedge Funds Holding BBNX

Farallon Capital holds 3.61M shares of BBNX, changed -16.37% as of Mar 31, 2026.
Soros Fund holds 25.00K shares of BBNX, changed -3.73% as of Jun 30, 2025.

Latest BBNX News

Beta Bionics Raises 2026 Guidance to 37–39% Growth, Adds 20 Sales Territories — Apr 22, 2026
Beta Bionics Adds 20 Territories, Targets Patch Pump Launch by 2027 — Mar 6, 2026
Beta Bionics Posts 54% Sales Surge, Boosts Gross Margin to 55.4%, but FDA Warning Weighs — Feb 18, 2026
Beta Bionics Raises 2025 Sales by 54%, Projects $130-135M in 2026 — Feb 17, 2026
Beta Bionics Predicts $30M Q4 Revenue; Analysts See 106.7% Upside — Feb 16, 2026

Recent BBNX Insider Trades

Hopman Mark sold 353 (~$4.08K) on Mar 4, 2026.
Hopman Mark sold 834 (~$10.31K) on Mar 2, 2026.
Russell Steven Jon sold 1.03K (~$12.68K) on Mar 2, 2026.

BBNX Analyst Consensus

8 analysts cover BBNX: 0 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.00.

Common questions about BBNX

Who owns BBNX stock?: Hedge funds tracked by Rallies that own BBNX include Farallon Capital and Soros Fund. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Beta Bionics, Inc. Common Stock.
Does Rallies show 13F holders for BBNX?: Yes. Rallies tracks hedge fund and 13F ownership data for BBNX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is BBNX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BBNX. It does not provide personalized investment advice.